Amoxicillin Chewable Tablets: What Is Available

Which Amoxicillin Chewable Strengths Are Documented?

For U.S. prescription products, the words tablet, chewable identify a dosage form, not merely a small tablet intended for children. The Chartwell RX generic label describes plain-amoxicillin chewables in 125 mg and 250 mg strengths. Separately, the USAntibiotics AMOXIL-derived prescribing text describes 125 mg, 200 mg, 250 mg, and 400 mg chewables. These are different label families, so a tablet imprint or ingredient list from one family must not be assigned to another.

The 200 mg and 400 mg AMOXIL-style strengths have their own FDA application history and are not invented dose subdivisions of the 125 mg and 250 mg generics. The reviewed USAntibiotics text includes package NDCs for those presentations, but that text is not a live inventory list. In particular, the DailyMed record updated July 7, 2026 currently surfaces NDCs for a suspension product at the top of the record; independent confirmation of actively listed chewable NDCs and retail supply is still necessary.

A strength printed in a label is evidence of a product description, not permission to replace the medicine written on a prescription. A clinician determines whether the infection warrants an antibiotic and what form is suitable; the dispensing pharmacist then confirms whether an appropriately authorized product can be provided.

Documented Chewable Products: Identifiers and Package Context

The examples below illustrate different levels of product evidence. The Chartwell 125 mg and 250 mg records identify specific generic packages, while Northwind has a separate repackaged 250 mg NDC. The USAntibiotics 200 mg and 400 mg examples are NDCs printed in the How Supplied portion of its consolidated prescribing text; they must not be represented as currently available packages simply because the text was updated.

Chartwell and Northwind details were checked against their respective 2026 DailyMed records. The USAntibiotics prescribing information says revised May 2024, while the reviewed electronic DailyMed record was updated July 7, 2026. Those are document dates, not inventory timestamps. The table is a selection of verifiable labels, not a ranking of manufacturers, a complete active NDC directory, or a pharmacy offer.

What 93/2267, 93/2268, and AMOXIL Imprints Tell You

Within the Chartwell-labeled family, 93/2267 identifies the 125 mg chewable and 93/2268 identifies the 250 mg chewable. The reviewed labels describe both as white to off-white, whereas the AMOXIL-marked 200 mg and 400 mg chewables are described as pale-pink, round tablets. Those visible differences are useful clues only when the exact label family and product record are known; color or shape alone cannot authenticate a dispensed medicine.

An AMOXIL imprint does not settle whether an item in a pharmacy catalog is being sold as a currently marketed branded product, an authorized generic, or another lawful presentation. The corresponding approved application, labeler information and specific package record establish those distinctions. Conversely, a 93/2268 marking may appear under an original labeler or repackager with a different NDC without making the two package codes identical.

The 250 mg 93/2268 tablet has a partial bisect in the reviewed labeling, but a groove is not a stand-alone instruction to split it, alter the amount taken or improvise a different prescription strength. If a refill changes appearance, a pharmacist should reconcile the imprint with the dispensed NDC and directions before use.

Understanding ANDA, Authorized Generics, NDCs, and Repackagers

ANDA identifies the regulatory approval pathway for a generic drug product, while an NDC identifies a listed drug product and, with its package segment, a labeled package configuration. An NDC appearing in a document is not a separate FDA approval certificate, does not establish therapeutic equivalence by itself, and is not proof that a pharmacy can ship the item today. A labeler may be different from the company that physically manufactured a tablet.

Chartwell 125 mg and 250 mg chewables are documented under generic ANDA 064013. Northwind’s 250 mg listing identifies a repackaged product with NDC 82868-063-30 and source NDC family 0093-2268; that packaging relationship should not be counted as another newly approved strength. The AMOXIL-style 200 mg and 400 mg chewables belong to a separate NDA-derived product history, and older How Supplied codes must be assessed for current status rather than treated as confirmed orders.

To resolve an unfamiliar pharmacy listing, have the dispensing pharmacist compare the active ingredient, labeled strength, chewable form, product identity, relevant application and actual dispensed package. The FDA-approved amoxicillin products guide covers application and listing checks in greater detail.

Chewables and Suspension Solve Different Practical Problems

A chewable has a fixed labeled quantity of amoxicillin per tablet; a powder for oral suspension becomes a measured liquid after a pharmacy prepares it. Liquid products use a concentration expressed in mg per 5 mL, and require an appropriate measuring device and instructions for storage and disposal after reconstitution. Neither the appearance of a chewable nor the number on a liquid bottle makes the two presentations automatically substitutable.

An individual who cannot chew reliably may need a different prescribed form, but the choice is not made by comparing only the active-ingredient number. The clinician and pharmacist should assess whether a different formulation is suitable and whether a revised order is required. This page stays focused on the chewable purchasing decision; preparation and liquid-specific handling belong in the separate suspension product catalog.

Sweeteners, Aspartame, and Phenylalanine: Check the Exact Label

The inactive ingredients are not uniform across chewable amoxicillin products. Chartwell’s reviewed 125 mg and 250 mg generic labels list cherry flavor, anhydrous lactose, mannitol, sucrose and other tablet-making ingredients. The USAntibiotics AMOXIL-derived text instead describes mannitol, glycine, saccharin sodium and confectioner’s sugar, among other components, for its 125 mg and 250 mg chewables. A shared active ingredient does not make those formulations identical in taste, excipients or physical characteristics.

The 200 mg and 400 mg chewables described in the USAntibiotics label contain aspartame, which supplies phenylalanine. The specified quantities are 1.82 mg of phenylalanine per 200 mg tablet and 3.64 mg per 400 mg tablet. That distinction is particularly relevant for someone with phenylketonuria (PKU). It would be incorrect to carry these amounts over to Chartwell 125 mg or 250 mg tablets, or to assume that all other chewables are aspartame-free without checking their actual ingredient statements.

A patient or caregiver managing PKU, a known excipient intolerance or a serious drug allergy should raise that information with the clinician and pharmacist before dispensing. A product-specific label is more dependable than generalized claims such as “all chewables are sugar-free” or “all cherry-flavored versions contain the same sweetener.” A history of serious penicillin or related beta-lactam hypersensitivity also requires medical review independently of sweetener concerns.

Who Can Use a Chewable Form? Age Alone Is Not the Answer

Chewable tablets can be a useful presentation for some patients who cannot swallow ordinary tablets, but this does not make them automatically suitable for all children or adults. The ability to chew and swallow safely, medical history, allergies, available formulations and the clinical need for an antibiotic all matter. A child who cannot reliably chew a tablet should not be encouraged to swallow or manipulate one without professional instructions.

Antibiotics are not automatically required for a sore throat, fever, cough or cold. A clinician decides whether findings support a bacterial infection and whether amoxicillin is appropriate; new or severe symptoms may require an examination or testing rather than product shopping. An urgent reaction such as difficulty breathing or severe allergy symptoms warrants prompt medical attention, not a different checkout option.

How to Confirm That a Pharmacy Can Actually Supply the Chewable

Online product search boxes frequently abbreviate the name to “amoxicillin 250 mg,” which can refer to several distinct oral forms. Ask the dispensing pharmacy to confirm plain amoxicillin, chewable tablet, prescribed strength and quantity from the actual prescription record. For product-specific questions, request the expected labeler or package information, but do not insist on a particular historical NDC if the pharmacy can only verify an appropriately authorized current product.

A supplier catalog, package NDC or generalized in-stock badge is not confirmation that a patient-specific prescription is ready. The pharmacy may need time for product sourcing, clinical review or a prescriber clarification. Before traveling, ask whether the ordered chewable form is physically available, whether it must be ordered, and when dispensing is expected. The local pharmacy guide covers general pickup and timing questions.

For online ordering, a seller that offers prescription amoxicillin without a valid prescription or will not identify the dispensing pharmacy should not be treated as legitimate merely because it advertises chewables. More detailed licensing checks belong on the online pharmacy verification page.

Comparing the Real Cost of a Chewable Prescription

The cheapest advertised amoxicillin capsule is not a useful price quote for a specified chewable prescription. Total patient cost can depend on the exact product, the number of tablets actually dispensed, pharmacy acquisition and cash pricing, insurance treatment of the product, and whether special ordering or delivery adds a charge. A manufacturer bottle containing 60 tablets does not mean the patient is automatically prescribed or charged for 60 tablets.

Ask for an itemized or final out-of-pocket quote for the same chewable strength, dosage form and authorized quantity, and clarify whether any quoted price assumes insurance or a discount card. If a pharmacy cannot source the prescribed presentation, a different listed product price is not a substitute for a clinician-authorized dispensing decision. General pricing methodology appears on the amoxicillin price page; no retailer-specific current prices are asserted here.

A Concise Check When the Chewables Are Dispensed

At pickup or delivery, compare the pharmacy label with the prescription for plain amoxicillin, chewable form, strength, directions and quantity. The physical tablet and the pharmacy’s product record should be reconcilable; an unexpectedly different imprint or ingredient list merits a question before the medicine is used. This is especially important when a refill comes from a different labeler or repackager.

Ask for instructions on chewing and on handling or storage for that specific product, rather than generalizing from a different amoxicillin formulation. Keep the medicine in its properly labeled container and out of children’s reach. If the identity remains unclear, have the pharmacist resolve it instead of using online pill photographs as a substitute for verification.

What If the Prescribed Chewable Is Unavailable?

It is possible for a pharmacy to stock amoxicillin capsules or suspension without being able to dispense a particular chewable. A pharmacist can determine whether the prescribed product can be sourced or an approved equivalent product can be dispensed under applicable rules. If a different dosage form or strength is being considered, the prescriber may need to make a separate clinical decision; the patient should not recalculate the amount or change the form independently.

Augmentin chewables are not plain-amoxicillin chewables. Augmentin includes clavulanate, and its strengths describe a two-component product. A matching amoxicillin number does not authorize switching between the medicines. The Augmentin chewable guide addresses that separate formulation.

When fulfillment cannot proceed, ask the pharmacy to identify the specific obstacle: missing valid authorization, unavailable chewable stock, an ingredient concern, a clarification from the prescriber, or an unresolved insurance claim. Each has a different responsible party and next step. There is no assurance that an alternate product, immediate delivery or a prescription change will be possible.

Three Questions That Reveal a Mismatched Product Listing

“Does AMOXIL 400 mean a 400 mg chewable is available to order?” Not necessarily. The USAntibiotics prescribing text documents a 400 mg chewable with AMOXIL imprint and package codes, but the current electronic listing must be checked separately for active product and package status. The pharmacist can establish whether a lawful, actually dispensable item exists rather than relying on an archived How Supplied description.

“Is Northwind 250 mg a different antibiotic from Chartwell 250 mg?” Both reviewed records concern plain amoxicillin chewables, but they identify different labeling and package records. Northwind’s repackaged NDC points to a source NDC family, not to a new active ingredient. The precise dispensed product still requires a pharmacist’s confirmation.

“If a patient has PKU, can any chewable formulation be selected?” No. The reviewed 200 mg and 400 mg AMOXIL-derived formulations disclose phenylalanine from aspartame, whereas other label families have different ingredients. The clinician and pharmacist should review the specific product rather than selecting a chewable by strength, flavor or price alone.